These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 7804823)

  • 1. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Andersen JK; Frim DM; Isacson O; Beal MF; Breakefield XO
    Brain Res; 1994 Sep; 656(1):108-14. PubMed ID: 7804823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex-related effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine treatment may be related to differences in monoamine oxidase B.
    Unzeta M; Baron S; Perez V; Ambrosio S; Mahy N
    Neurosci Lett; 1994 Aug; 176(2):235-8. PubMed ID: 7830954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical evaluation of the neurotoxicity of MPTP and MPP⁺ in embryonic and newborn mice.
    Sai T; Uchida K; Nakayama H
    J Toxicol Sci; 2013; 38(3):445-58. PubMed ID: 23665943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.
    Przedborski S; Kostic V; Jackson-Lewis V; Naini AB; Simonetti S; Fahn S; Carlson E; Epstein CJ; Cadet JL
    J Neurosci; 1992 May; 12(5):1658-67. PubMed ID: 1578260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
    Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
    Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Melamed E; Rosenthal J; Youdim MB
    J Neurochem; 1990 Oct; 55(4):1427-31. PubMed ID: 2398363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
    Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
    J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Youngster SK; Sonsalla PK; Heikkila RE
    J Neurochem; 1987 Mar; 48(3):929-34. PubMed ID: 3492590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
    Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
    Mohanakumar KP; Muralikrishnan D; Thomas B
    Brain Res; 2000 May; 864(2):281-90. PubMed ID: 10802035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuroblastic apoptosis in the subventricular zone is caused by 1-methy-4-phenylpiridinium (MPP(+)) converted from MPTP through MAO-B.
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2012 Nov; 64(7-8):761-5. PubMed ID: 21324658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine-releasing action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) in the neostriatum of the rat as demonstrated in vivo by the push-pull perfusion technique: dependence on sodium but not calcium ions.
    Sirinathsinghji DJ; Heavens RP; McBride CS
    Brain Res; 1988 Mar; 443(1-2):101-16. PubMed ID: 3258784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.
    Heikkila RE; Manzino L; Cabbat FS; Duvoisin RC
    Nature; 1984 Oct 4-10; 311(5985):467-9. PubMed ID: 6332989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
    Morgan WW; Nelson JF
    Brain Res; 2001 Dec; 921(1-2):115-21. PubMed ID: 11720717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity.
    Castagnoli K; Palmer S; Castagnoli N
    Neurobiology (Bp); 1999; 7(2):135-49. PubMed ID: 10591048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity.
    Oeckl P; Ferger B
    Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.